About Us
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 45 years.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 45 years.
Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
We celebrate our unique history as the pioneers of scientific breakthroughs that have an incredible track record of improving lives. And yet, our ambitions are bigger and bolder. Together, we are united in a bold quest to solve the world’s most complex health challenges and serve society.
Our ability to bring transformative medicines to patients depends on the positive experience, engagement and resilience of everyone who works here. Our employees are the heart of Genentech and the driving force behind the progress that brings important new medicines to the people who need them. We believe a great people experience is critical for revolutionizing healthcare and living Our Promise. That’s why we’re committed to cultivating an environment where people feel valued, included and able to thrive.
A Member of the Roche Group
Genentech became a member of the Roche Group in March of 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech's South San Francisco campus serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development continues to embrace the spirit of a “startup” and operates as a separate business unit within Roche.
